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Performance characteristics of two automated 
solid-phase red cell adherence systems for 
pretransfusion antibody screening:  
a cautionary tale
K. Quillen, J. Caron, and K. Murphy
RepoRt
Our institution has implemented two instruments, the Galileo and 
the Echo, that use different solid-phase red cell adherence assays 
for antibody screening in pretransfusion compatibility testing. 
During the initial implementation of these two instruments, we 
noticed very different problems: falsely positive results on the 
Galileo, and falsely negative results and lack of reproducibility 
on the Echo. Comparison of falsely positive antibody screen 
results from approximately equivalent numbers of samples run 
on the Galileo and samples tested by standard manual tube 
technique using low-ionic-strength saline enhancement showed 
a false-positive rate of 1.4 percent on the Galileo (defined as a 
positive screen with a negative panel). Testing using the Echo 
identified four cases of falsely negative antibody screens, (defined 
as a negative screen on a patient sample subsequently shown to 
be positive by the same method). In addition, we note a lack of 
reproducibility on the Echo, which emphasizes the importance 
of replicate testing during validation of automated antibody 
screening platforms. Immunohematology 2012;28:137–9.
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Our institution was one of the early adopters of blood bank 
automation. In 2005, we implemented a large throughput, 
walkaway instrument (Galileo, Immucor, Norcross, GA), 
which uses a solid-phase red cell adherence (SPRCA) assay 
for antibody screening. Before that, we used manual tube 
method with low-ionic-strength saline (LISS) enhancement 
for routine pretransfusion antibody screening, reserving ficin 
and polyethylene glycol (PEG) for individualized workups. We 
continue to use tube testing with LISS for stat samples and 
during low-volume shifts.
The Galileo instrument offers walkaway automation with 
random access capability. In our validation testing, it was 
more sensitive than LISS, consistent with other reports. More 
recently, we added a second SPRCA assay instrument (Echo, 
Immucor), after an abbreviated validation that demonstrated 
100 percent concordance between Echo and Galileo results 
on almost 150 specimens. During the initial implementation 
of these two instruments, we noticed very different problems: 
falsely positive results on the Galileo, and falsely negative 
results and lack of reproducibility on the Echo. These issues 
form the basis of this report.
Materials and Methods
Galileo Testing
For a 7-week phase-in period in 2006, samples for antibody 
screening (ABSC) were tested by manual tube method with 
LISS (tube, three-cell screen) or on the Galileo (two-cell screen), 
depending on the urgency of the transfusion or availability of 
a trained operator. Positive ABSC results on the Galileo were 
investigated with a panel on the instrument. Inconclusive 
Galileo panels, defined as those in which no antibody specificity 
was identified, were followed by a manual PEG panel. The 
Galileo ABSC result is considered falsely positive if the Galileo 
panel is negative or if the PEG panel is negative. Positive LISS 
ABSC results were followed up with LISS panels.
Echo Testing
Within the first few months of implementation of the Echo, 
in 2011, using the latest software (v 1.2.2) and a three-cell 
screen (Capture-R Ready-Screen [3], Immucor), we noticed 
four cases of negative antibody screens in patients known to 
have positive screens on recent prior specimens. Manual visual 
review of these negative results was equivocal. We noticed 
that one of the index samples was interpreted as equivocal on 
one run, which was manually interpreted as negative, then 
3+ on a subsequent run of the same instrument using the 
same lot of reagents. We selected 29 additional samples with 
positive antibody screens (by Galileo testing), and reran each 
specimen multiple times on the Echo. The replicate testing 
was performed with the same reagent lot, typically within the 
same day. These samples were all less than 14 days old, and 
had been stored at 1° to 4°C, in accordance with the storage 
specifications of all patient samples at our institution.
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Results
Galileo Testing
A total of 3297 ABSCs were performed, of which 1362 
were done with Galileo testing. Of the 1362 Galileo ABSCs, 
67 (4.9%) were positive. In 13 cases, LISS panels had been 
completed within the prior 7 days or the specimen was not 
sufficient in quantity for further evaluation. Evaluating the 
remaining 54 positive ABSCs on the Galileo, 35 (64.8%) were 
true positives and 19 (35.2%) were false positives (Table 1). 
Of the 19 falsely positive Galileo ABSCs (19/1349 = 1.4% 
false-positive rate), 14 had negative Galileo panels and 5 had 
inconclusive Galileo panels (the latter 5 cases had negative 
PEG panels). Of the 1935 manual ABSCs, 27 LISS panels 
were performed of which 100 percent were true positives. We 
did not observe any patient-specific factors such as pregnancy 
or medications common to the falsely positive Galileo results, 
but the reaction values typically were low, just above the 
numeric cutoff threshold. These falsely positive Galileo ABSC 
results were reproducible on repeat automated testing (data 
not shown).
Echo Testing
During the period of live testing, 4 missed positive 
antibody screens were discovered in a total of 3838 tests 
performed (4/3838 = 0.1%). These samples tested negative 
on initial Echo ABSC, but raised suspicion because of records 
showing recent prior positive ABSCs. They are listed in 
Table 2. Only 1 patient had received any red blood cell (RBC) 
transfusions between tests (the second patient, who is a 
chronically transfused sickle cell patient). The true incidence 
of missing a positive antibody screen is likely much higher, 
in cases when the patient does not have any recent positive 
ABSC result for comparison.
Of the 29 samples with known positive antibody screens 
on the Galileo selected for replicate testing, 5 were discovered 
to have inconsistent results. These are detailed in Table 
3. The reaction strengths varied from 3+ to negative on a 
representative sample with anti-Fya.
Discussion
The goal of pretransfusion compatibility testing is to 
optimize the detection of clinically significant RBC antibodies 
in a timely and cost-effective algorithm. Automated SPRCA 
platforms have been extensively used in antibody screening 
of blood donors, a population in which the prevalence of 
alloimmunization is expected to be low. PEG is generally 
considered to be the most sensitive method for tube indirect 
antiglobulin testing.1 Manual SPRCA was found to rival PEG 
in sensitivity and specificity; automated SPRCA on an earlier 
instrument (ABS2000, Immucor) had a lower sensitivity than 
PEG and manual SPRCA but better specificity.2,3 We found that 
one third of positive ABSC results on Galileo may be falsely 
positive, with no identifiable specificity on Galileo or PEG panel 
testing.4 In our anecdotal experience during the past 6 years, 
falsely positive Galileo ABSC results have recurred in the same 
patient on subsequent samples over time and have not been 
associated with the subsequent detection of true alloantibodies. 
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Table 1. Positive antibody screen results on Galileo and using 
tube low-ionic-strength saline method
Number of samples Galileo Tube LISS Total
ABSC 1362 1935 3297
Positive ABSC 67 (4.9%) 27 (1.4%) 94 (2.9%)
Panels completed 54 27
True positive 35 27
False positive 19 0
ABSC = antibody screen; LISS = low-ionic-strength saline.
Table 2. Falsely negative antibody screen results on Echo
Known antibody 
specificities
Number of days 
from last positive 
screen
Result on prior 
ABSC (test 
method)
Result of repeat 





E 2 2+ (Galileo) 3+  anti-E (3+)
E 60 2+ (Galileo) 2+  anti-E (2+)
E 4 2+ (Echo)* 2+  anti-E (3+)
K 19 1+ (Galileo) 3+  anti-K (3+)
ABSC = antibody screen
*Same reagent lot
Table 3. Inconsistent antibody screen results on replicates of 
known positive specimens tested on the Echo
Antibody 
specificity
Number of  
replicates
Sequential results  
(number of replicates)
Antigen dosage on 
implicated cell
Fya 2 3+, ? Single dose
E, K, M 10 3+(×4), ?(×3),  
1+(×2), 2+
Double dose
Jka* 11 3+(×9), ?, 3+ Double dose
Fya 11 3+, 1+, ?(×2),  
2+, neg(×6)
Single dose
Jka* 11 3+(×8), ?(×2), 3+ Double dose
*Same patient, 2 different specimens.
? indicates an equivocal result reported on the instrument.
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Automated solid-phase antibody screening
They have not been detected at all in populations at high risk 
of alloimmunization such as chronically transfused sickle cell 
patients.
Falsely negative antibody screen results are of greater 
clinical concern; they have been reported with the Echo 
and attributed to a defective image analysis algorithm.5 The 
incidence of falsely negative antibody screens depends on how 
cases are identified and the prevalence of alloimmunization 
in the population studied. It varies from 0.02 percent in a 
single-institution retrospective study6 to 0.5 percent based on 
proficiency testing results in the United Kingdom.7
The lack of reproducibility on the Echo that we discovered 
has not been previously reported. Preanalytic factors such 
as lipemia and hemolysis were not implicated in the cases, 
and depletion of sample volume is unlikely because weaker 
(or even negative) results occurred in the middle of a 
sequence of replicates, rather than being skewed during the 
last run. Automation is a relatively recent innovation in the 
immunohematology testing arena compared with other areas 
of clinical laboratory testing, and the importance of replicate 
testing may not be widely appreciated. We submit this 
report as a cautionary tale that automated blood bank solid-
phase platforms from the same manufacturer may have very 
different performance characteristics and to emphasize the 
importance of replicate testing during validation. Heightened 
alertness during the initial implementation of a new test 
method is required to correlate current results with patients’ 
prior antibody screen results, despite the well-known problem 
of antibody evanescence.8
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